The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00829166




Registration number
NCT00829166
Ethics application status
Date submitted
22/01/2009
Date registered
22/01/2009
Date last updated
10/09/2016

Titles & IDs
Public title
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Scientific title
A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Secondary ID [1] 0 0
TDM4370g
Secondary ID [2] 0 0
BO21977
Universal Trial Number (UTN)
Trial acronym
EMILIA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Trastuzumab emtansine
Treatment: Drugs - Lapatinib
Treatment: Drugs - Capecitabine

Experimental: Trastuzumab emtansine - Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.

Active Comparator: Lapatinib + Capecitabine - Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.


Treatment: Drugs: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.

Treatment: Drugs: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.

Treatment: Drugs: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC) - PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
Timepoint [1] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Primary outcome [2] 0 0
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint) - Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
Timepoint [2] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Primary outcome [3] 0 0
Percentage of Participants Who Died: Second Interim Analysis - The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
Timepoint [3] 0 0
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Primary outcome [4] 0 0
Overall Survival: Second Interim Analysis (Co-primary Endpoint) - OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
Timepoint [4] 0 0
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Primary outcome [5] 0 0
Percentage of Participants Who Died: Final Analysis - The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
Timepoint [5] 0 0
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Primary outcome [6] 0 0
Overall Survival: Final Analysis - OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
Timepoint [6] 0 0
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Primary outcome [7] 0 0
Percentage of Participants Who Were Alive at Year 1 - 1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Timepoint [7] 0 0
Year 1
Primary outcome [8] 0 0
Percentage of Participants Who Were Alive at Year 2 - 2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Timepoint [8] 0 0
Year 2
Secondary outcome [1] 0 0
Percentage of Participants With PD or Death as Assessed by the Investigator - PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
Timepoint [1] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [2] 0 0
PFS as Assessed by the Investigator - Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
Timepoint [2] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [3] 0 0
Percentage of Participants With Objective Response (OR) as Assessed by an IRC - Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
Timepoint [3] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [4] 0 0
Duration of Objective Response (DOR) as Assessed by an IRC - Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
Timepoint [4] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [5] 0 0
Percentage of Participants With Clinical Benefit as Assessed by an IRC - Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
Timepoint [5] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [6] 0 0
Percentage of Participants With Treatment Failure - Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
Timepoint [6] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [7] 0 0
Time to Treatment Failure - Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
Timepoint [7] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [8] 0 0
Percentage of Participants With Symptom Progression - Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
Timepoint [8] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Secondary outcome [9] 0 0
Time to Symptom Progression - Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
Timepoint [9] 0 0
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Eligibility
Key inclusion criteria
- HER2 status must be prospectively, centrally tested and be HER2-positive based on
central laboratory assay results

- Histologically or cytologically confirmed invasive breast cancer

- Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or
metastatic setting must include both a taxane, alone or in combination with another
agent, and trastuzumab, alone or in combination with another agent

- Documented progression (which occur during or after most recent treatment or within 6
months after completing of adjuvant therapy) of incurable, unresectable, locally
advanced or metastatic breast cancer, defined by the investigator

- Measurable and/or nonmeasurable disease; participants with central nervous system-only
disease are excluded

- Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either
echocardiogram or multi-gated acquisition scan

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- For women of childbearing potential and men with partners of childbearing potential,
agreement to use a highly effective, non-hormonal form of contraception; contraception
use should continue for the duration of the study treatment and for at least 6 months
after the last dose of study treatment
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of treatment with trastuzumab emtansine

- Prior treatment with lapatinib or capecitabine

- Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE), Version 3.0

- History of other malignancy within the last 5 years, except for appropriately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer,
synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a
similar curative outcome as those mentioned above

- History of receiving any anti-cancer drug/biologic or investigational treatment within
21 days prior to randomization except hormone therapy, which could be given up to 7
days prior to randomization; recovery of treatment-related toxicity consistent with
other eligibility criteria

- History of radiation therapy within 14 days of randomization

- Brain metastases that are untreated, symptomatic, or require therapy to control
symptoms, as well as any history of radiation, surgery, or other therapy, including
steroids, to control symptoms from brain metastases within 2 months (60 days) of
randomization

- History of symptomatic congestive heart failure or serious cardiac arrhythmia
requiring treatment

- History of myocardial infarction or unstable angina within 6 months of randomization

- Current dyspnea at rest due to complications of advanced malignancy or current
requirement for continuous oxygen therapy

- Current severe, uncontrolled systemic disease (for example, clinically significant
cardiovascular, pulmonary, or metabolic disease)

- Pregnancy or lactation

- Current known active infection with human immunodeficiency virus (HIV), hepatitis B
virus, or hepatitis C virus

- Presence of conditions that could affect gastrointestinal absorption: Malabsorption
syndrome, resection of the small bowel or stomach, and ulcerative colitis

- History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab

- Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase
deficiency

- Current treatment with sorivudine or its chemically related analogs, such as brivudine

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Minnesota
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
Montana
Country [21] 0 0
United States of America
State/province [21] 0 0
Nebraska
Country [22] 0 0
United States of America
State/province [22] 0 0
Nevada
Country [23] 0 0
United States of America
State/province [23] 0 0
New Jersey
Country [24] 0 0
United States of America
State/province [24] 0 0
New Mexico
Country [25] 0 0
United States of America
State/province [25] 0 0
New York
Country [26] 0 0
United States of America
State/province [26] 0 0
North Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oregon
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
Rhode Island
Country [31] 0 0
United States of America
State/province [31] 0 0
South Carolina
Country [32] 0 0
United States of America
State/province [32] 0 0
Tennessee
Country [33] 0 0
United States of America
State/province [33] 0 0
Texas
Country [34] 0 0
United States of America
State/province [34] 0 0
Virginia
Country [35] 0 0
United States of America
State/province [35] 0 0
Washington
Country [36] 0 0
United States of America
State/province [36] 0 0
Wisconsin
Country [37] 0 0
Bosnia and Herzegovina
State/province [37] 0 0
Banja Luka
Country [38] 0 0
Bosnia and Herzegovina
State/province [38] 0 0
Sarajewo
Country [39] 0 0
Brazil
State/province [39] 0 0
Belo Horizonte
Country [40] 0 0
Brazil
State/province [40] 0 0
Curitiba
Country [41] 0 0
Brazil
State/province [41] 0 0
Goiania
Country [42] 0 0
Brazil
State/province [42] 0 0
Itajai
Country [43] 0 0
Brazil
State/province [43] 0 0
JAU
Country [44] 0 0
Brazil
State/province [44] 0 0
Joao Pessoa
Country [45] 0 0
Brazil
State/province [45] 0 0
Porto Alegre - Rs
Country [46] 0 0
Brazil
State/province [46] 0 0
Porto Alegre
Country [47] 0 0
Brazil
State/province [47] 0 0
Rio de Janeiro
Country [48] 0 0
Brazil
State/province [48] 0 0
Santo Andre
Country [49] 0 0
Brazil
State/province [49] 0 0
Sao Paulo
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Plovdiv
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Sofia
Country [52] 0 0
Bulgaria
State/province [52] 0 0
Varna
Country [53] 0 0
Canada
State/province [53] 0 0
Alberta
Country [54] 0 0
Canada
State/province [54] 0 0
British Columbia
Country [55] 0 0
Canada
State/province [55] 0 0
Nova Scotia
Country [56] 0 0
Canada
State/province [56] 0 0
Ontario
Country [57] 0 0
Canada
State/province [57] 0 0
Quebec
Country [58] 0 0
Colombia
State/province [58] 0 0
Bogota
Country [59] 0 0
Colombia
State/province [59] 0 0
Monteria
Country [60] 0 0
Denmark
State/province [60] 0 0
Herlev
Country [61] 0 0
Denmark
State/province [61] 0 0
København
Country [62] 0 0
Denmark
State/province [62] 0 0
Odense
Country [63] 0 0
Finland
State/province [63] 0 0
Helsinki
Country [64] 0 0
Finland
State/province [64] 0 0
Tampere
Country [65] 0 0
Finland
State/province [65] 0 0
Turku
Country [66] 0 0
France
State/province [66] 0 0
Avignon
Country [67] 0 0
France
State/province [67] 0 0
Bordeaux
Country [68] 0 0
France
State/province [68] 0 0
Brest
Country [69] 0 0
France
State/province [69] 0 0
Caen
Country [70] 0 0
France
State/province [70] 0 0
Dijon
Country [71] 0 0
France
State/province [71] 0 0
La Roche Sur Yon
Country [72] 0 0
France
State/province [72] 0 0
Montpellier
Country [73] 0 0
France
State/province [73] 0 0
Paris
Country [74] 0 0
France
State/province [74] 0 0
Saint Brieuc
Country [75] 0 0
France
State/province [75] 0 0
Saint Herblain
Country [76] 0 0
France
State/province [76] 0 0
Vandoeuvre-les-nancy
Country [77] 0 0
Germany
State/province [77] 0 0
Aschaffenburg
Country [78] 0 0
Germany
State/province [78] 0 0
Berlin
Country [79] 0 0
Germany
State/province [79] 0 0
Bonn
Country [80] 0 0
Germany
State/province [80] 0 0
Dortmund
Country [81] 0 0
Germany
State/province [81] 0 0
Freiburg
Country [82] 0 0
Germany
State/province [82] 0 0
Fuerstenwalde
Country [83] 0 0
Germany
State/province [83] 0 0
Hamburg
Country [84] 0 0
Germany
State/province [84] 0 0
Karlsruhe
Country [85] 0 0
Germany
State/province [85] 0 0
Kiel
Country [86] 0 0
Germany
State/province [86] 0 0
Offenbach
Country [87] 0 0
Germany
State/province [87] 0 0
Stralsund
Country [88] 0 0
Hong Kong
State/province [88] 0 0
Hong Kong
Country [89] 0 0
India
State/province [89] 0 0
Bangalore
Country [90] 0 0
India
State/province [90] 0 0
Gurgaon
Country [91] 0 0
India
State/province [91] 0 0
Kolkata
Country [92] 0 0
India
State/province [92] 0 0
New Delhi
Country [93] 0 0
India
State/province [93] 0 0
Pune
Country [94] 0 0
Italy
State/province [94] 0 0
Aviano
Country [95] 0 0
Italy
State/province [95] 0 0
Bologna
Country [96] 0 0
Italy
State/province [96] 0 0
Candiolo
Country [97] 0 0
Italy
State/province [97] 0 0
Genova
Country [98] 0 0
Italy
State/province [98] 0 0
Meldola
Country [99] 0 0
Italy
State/province [99] 0 0
Milano
Country [100] 0 0
Italy
State/province [100] 0 0
Napoli
Country [101] 0 0
Italy
State/province [101] 0 0
Negrar
Country [102] 0 0
Italy
State/province [102] 0 0
Pisa
Country [103] 0 0
Italy
State/province [103] 0 0
Reggio Emilia
Country [104] 0 0
Italy
State/province [104] 0 0
Roma
Country [105] 0 0
Italy
State/province [105] 0 0
Rozzano
Country [106] 0 0
Italy
State/province [106] 0 0
Sassari
Country [107] 0 0
Italy
State/province [107] 0 0
Terni
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Kyunggi-do
Country [109] 0 0
Korea, Republic of
State/province [109] 0 0
Seoul
Country [110] 0 0
Mexico
State/province [110] 0 0
Acapulco
Country [111] 0 0
Mexico
State/province [111] 0 0
Oaxaca
Country [112] 0 0
Mexico
State/province [112] 0 0
Toluca
Country [113] 0 0
New Zealand
State/province [113] 0 0
Newtown
Country [114] 0 0
New Zealand
State/province [114] 0 0
Palmerston North
Country [115] 0 0
Philippines
State/province [115] 0 0
Diliman, Quezon City
Country [116] 0 0
Philippines
State/province [116] 0 0
Quezon City, Luzon
Country [117] 0 0
Poland
State/province [117] 0 0
Bialystok
Country [118] 0 0
Poland
State/province [118] 0 0
Gdansk
Country [119] 0 0
Poland
State/province [119] 0 0
Krakow
Country [120] 0 0
Poland
State/province [120] 0 0
Lublin
Country [121] 0 0
Poland
State/province [121] 0 0
Opole
Country [122] 0 0
Poland
State/province [122] 0 0
Poznan
Country [123] 0 0
Poland
State/province [123] 0 0
Warszawa
Country [124] 0 0
Portugal
State/province [124] 0 0
Coimbra
Country [125] 0 0
Portugal
State/province [125] 0 0
Lisboa
Country [126] 0 0
Portugal
State/province [126] 0 0
Porto
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Kemerovo
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Moscow
Country [129] 0 0
Russian Federation
State/province [129] 0 0
St Petersburg
Country [130] 0 0
Singapore
State/province [130] 0 0
Singapore
Country [131] 0 0
Slovenia
State/province [131] 0 0
Ljubljana
Country [132] 0 0
Spain
State/province [132] 0 0
Barcelona
Country [133] 0 0
Spain
State/province [133] 0 0
Córdoba
Country [134] 0 0
Spain
State/province [134] 0 0
Lerida
Country [135] 0 0
Spain
State/province [135] 0 0
Madrid
Country [136] 0 0
Spain
State/province [136] 0 0
Santander
Country [137] 0 0
Spain
State/province [137] 0 0
Sevilla
Country [138] 0 0
Spain
State/province [138] 0 0
Valencia
Country [139] 0 0
Spain
State/province [139] 0 0
Zaragoza
Country [140] 0 0
Sweden
State/province [140] 0 0
Eskilstuna
Country [141] 0 0
Sweden
State/province [141] 0 0
Gaelve
Country [142] 0 0
Sweden
State/province [142] 0 0
Goteborg
Country [143] 0 0
Switzerland
State/province [143] 0 0
Luzern
Country [144] 0 0
Switzerland
State/province [144] 0 0
St. Gallen
Country [145] 0 0
Taiwan
State/province [145] 0 0
Kaohsung
Country [146] 0 0
Taiwan
State/province [146] 0 0
Taichung
Country [147] 0 0
Taiwan
State/province [147] 0 0
Taipei
Country [148] 0 0
Taiwan
State/province [148] 0 0
Taoyuan
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Bournemouth
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Cardiff
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Denbigh
Country [152] 0 0
United Kingdom
State/province [152] 0 0
London
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Manchester
Country [154] 0 0
United Kingdom
State/province [154] 0 0
New Castle Upon Tyne
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Northwood
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Poole
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Preston
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Romford
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Sutton
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Weston Super Mare

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial
designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of
capecitabine + lapatinib in participants with human epidermal growth factor receptor 2
(HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated
until disease progression (PD), unmanageable toxicity, or study termination. Once disease
progression is reported, all participants will be followed for survival every 3 months until
death, loss to follow-up, withdrawal of consent, or study termination.
Trial website
https://clinicaltrials.gov/show/NCT00829166
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Genentech, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Other publications